Kronox Lab Sciences Open Offer at ₹157.27 in 2026

Control shift triggers a mandatory open offer

Kronox Lab Sciences Ltd is heading into a change of control after its promoters executed a Share Purchase Agreement (SPA) with Indo Borax & Chemicals Limited and Zenrock Chemicals Private Limited. The transaction involves the sale of a controlling stake, followed by a mandatory open offer to public shareholders under the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filings outline both the negotiated acquisition price paid to the promoters and the separate open offer price for the remaining shareholders.

The disclosures also indicate that the change is not limited to ownership. The company has communicated that board and management control will transition to the acquirer group after completion, including nomination of directors and resignation of outgoing promoter-directors.

Who is buying and who is selling

The sellers are the company’s existing promoters: Ketan Vinodchandra Ramani, Pritesh Vinodchandra Ramani, and Jogindersingh Gianchand Jaswal. In aggregate, these promoters were disclosed as holding 74.21% of Kronox Lab Sciences before the transaction.

The acquirer is Indo Borax & Chemicals Limited, with Zenrock Chemicals Private Limited disclosed as a person acting in concert (PAC). Post-completion, Indo Borax is expected to be classified as the new promoter, while Zenrock is expected to be part of the promoter group.

SPA details: 64.26% stake sold at ₹103.22 per share

Kronox Lab Sciences informed exchanges that the SPA covers the sale of 2,38,44,000 equity shares, representing approximately 64.26% of the company’s total paid-up equity share capital. The consideration disclosed for this negotiated block deal is ₹246.12 crore.

The per-share price under the SPA is stated at ₹103.22. The filings also mention ₹105.87 per share including fees or consultancy-linked consideration. The agreement date disclosed for the SPA is August 20, 2026.

One disclosure summarised the impact clearly: completion of the SPA results in Indo Borax holding approximately 64.26% of the paid-up equity share capital, leading to a change in promoters and in the management and control of the company.

Open offer terms: up to 25.79% at ₹157.27 per share

After the SPA, a mandatory open offer is planned for public shareholders. Kronox Lab Sciences received a Draft Letter of Offer (DLOF) for an open offer from Indo Borax & Chemicals and Zenrock Chemicals to acquire up to 25.79% of its equity shares.

The open offer price is disclosed as ₹157.27 per share. If fully accepted, the total consideration would amount to ₹150.51 crore. The tendering period is set from October 15 to October 29, 2026.

The filings also note that the open offer follows a prior acquisition of 64.26% from existing sellers, and that the process is tied to the resulting change of control.

What changes in governance and board structure

The transaction is described as bringing a shift in management and control. Indo Borax is expected to appoint three nominee directors to Kronox’s board. The outgoing promoters are expected to resign as directors following completion of the transaction.

The company also indicated that the sellers will cease to be in control of Kronox and be reclassified as public shareholders upon completion. Indo Borax will become the promoter, with Zenrock as the promoter-group entity.

Separately, at the company’s 17th AGM held on September 16, 2026, shareholders reappointed Jogindersingh Jaswal as Chairman and approved a final dividend for FY26.

Dividend and AGM: ₹0.50 per share for FY26

Kronox Lab Sciences shareholders approved a ₹0.50 per share final dividend for FY26. The same 17th AGM, held on September 16, 2026, also saw the reappointment of Chairman Jogindersingh Jaswal.

The AGM outcome is notable because the company is simultaneously disclosing a control transfer process. Even so, the filings state the governance changes associated with the acquirer’s nominee appointments and the sellers’ resignations will happen upon completion of the SPA transaction.

Board meeting schedule for quarterly results

Kronox Lab Sciences also disclosed a scheduled board meeting to consider and approve unaudited standalone financial results for the quarter ended June 30, 2026. The company indicated the meeting was scheduled for August 12, 2026. The same agenda also included fixing the date of the AGM.

Shareholding pattern: promoters at 74.21%, FIIs almost nil

The shareholding pattern cited shows promoter holding at 74.21%, FII holding at 0.04%, DII holding at 0%, and public holding at 23.68%. The disclosures also state that promoter holding in the company has almost stayed constant over recent quarters.

One table shared in the data shows promoters at 74.21% across Jun 2025, Sep 2025, Dec 2025, Mar 2026, and Jun 2026. Another line mentions promoter holding remained unchanged at 74.18% as of March 31, 2026.

Key shareholding snapshot

Timeline and deal terms at a glance

The transaction and open offer process includes multiple dated events disclosed through filings and announcements.

Market impact

The disclosures outline a change in control from the founding promoter group to Indo Borax & Chemicals, with Zenrock Chemicals as PAC. Such transactions typically matter to investors because they reshape promoter classification, board composition, and strategic control, all of which are explicitly referenced in the filings.

The transaction also creates two distinct reference prices in the public domain: ₹103.22 per share (SPA) for the negotiated promoter block and ₹157.27 per share (open offer) for tendering shareholders. The filing further states the open offer can take the acquirer group’s ownership to over 90% if fully accepted.

Analysis: why this transaction is significant

The core significance lies in the fact pattern disclosed: 64.26% is being transferred through an SPA, and the acquirer will be the new promoter with the right to appoint three nominee directors. That combination signals a definitive shift in governance and control rather than a passive financial investment.

Another noteworthy element is the promoter holding stability disclosed over recent quarters, followed by a large negotiated transfer. The filings also note the sellers will retain an aggregate 9.95% stake after the transaction, while ceasing to be in control and moving to the public category upon completion.

Conclusion

Kronox Lab Sciences is set for a promoter transition after the SPA signed on August 20, 2026 for a 64.26% stake sale to Indo Borax & Chemicals, with Zenrock Chemicals acting in concert. A mandatory open offer for up to 25.79% at ₹157.27 per share is scheduled to run from October 15 to October 29, 2026. Investors will track the open offer process, completion milestones, and the board changes, including nomination of three directors by the acquirer and resignation of outgoing promoter-directors.